C‐reactive protein and tumor necrosis factor‐alpha in relation to insulin‐mediated glucose uptake, smoking and atherosclerosis

References

• Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta‐analyses. Br Med J 2000; 321: 199–204
   PubMed Web of Science ®Google Scholar
• Ridker P. M. High‐sensitivity C‐reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–18
   PubMed Web of Science ®Google Scholar
• Lagrand W. K., Visser C. A., Hermens W. T., Niessen H. W., Verheugt F. W., Wolbink G. J., et al. C‐reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 1999; 100: 96–102
   PubMed Web of Science ®Google Scholar
• Tataru M. C., Heinrich J., Junker R., Schulte H., von Eckardstein A., Assmann G., et al. C‐reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21: 1000–8
   PubMedGoogle Scholar
• Hulthe J., Wikstrand J., Fagerberg B. Relationship between C‐reactive protein and intima‐media thickness in the carotid and femoral arteries and to antibodies against oxidized low‐density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study. Clin Sci (Lond) 2001; 100: 371–8
   PubMed Web of Science ®Google Scholar
• Hak A. E., Stehouwer C. D., Bots M. L., Polderman K. H., Schalkwijk C. G., Westendorp I. C., et al. Associations of C‐reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle‐aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986–91
   PubMed Web of Science ®Google Scholar
• Tracy R. P., Psaty B. M., Macy E., Bovill E. G., Cushman M., Cornell E. S., et al. Lifetime smoking exposure affects the association of C‐reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17: 2167–76
   PubMed Web of Science ®Google Scholar
• Mendall M. A., Patel P., Ballam L., Strachan D., Northfield T. C. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J 1996; 312: 1061–5
   PubMed Web of Science ®Google Scholar
• Festa A., D'Agostino R., Jr., Howard G., Mykkanen L., Tracy R. P., Haffner S. M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–7
   PubMed Web of Science ®Google Scholar
• Lemieux I., Pascot A., Prud'homme D., Almeras N., Bogaty P., Nadeau A., et al. Elevated C‐reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21: 961–7
   PubMed Web of Science ®Google Scholar
• Heinrich P. C., Castell J. V., Andus T. Interleukin‐6 and the acute phase response. Biochem J 1990; 265: 621–36
   PubMed Web of Science ®Google Scholar
• Stephens J. M., Butts M. D., Pekala P. H. Regulation of transcription factor mRNA accumulation during 3T3‐L1 preadipocyte differentiation by tumour necrosis factor‐alpha. J Mol Endocrinol 1992; 9: 61–72
   PubMedGoogle Scholar
• Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor‐alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–15
   PubMed Web of Science ®Google Scholar
• Mohamed‐Ali V., Goodrick S., Rawesh A., Katz D. R., Miles J. M., Yudkin J. S., et al. Subcutaneous adipose tissue releases interleukin‐6, but not tumor necrosis factor‐alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196–200
   PubMed Web of Science ®Google Scholar
• Yudkin J. S., Stehouwer C. D., Emeis J. J., Coppack S. W. C‐reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction – a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999; 19: 972–8
   PubMed Web of Science ®Google Scholar
• Hotamisligil G. S., Spiegelman B. M. Tumor necrosis factor alpha: a key component of the obesity‐diabetes link. Diabetes 1994; 43: 1271–8
   PubMed Web of Science ®Google Scholar
• Hotamisligil G. S., Budavari A., Murray D., Spiegelman B. M. Reduced tyrosine kinase activity of the insulin receptor in obesity‐diabetes. Central role of tumor necrosis factor‐alpha. J Clin Invest 1994; 94: 1543–9
   PubMed Web of Science ®Google Scholar
• Hardardottir I., Grunfeld C., Feingold K. R. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994; 5: 207–15
   PubMedGoogle Scholar
• Kawakami M., Pekala P. H., Lane M. D., Cerami A. Lipoprotein lipase suppression in 3T3‐L1 cells by an endotoxin‐induced mediator from exudate cells. Proc Natl Acad Sci USA 1982; 79: 912–16
   PubMed Web of Science ®Google Scholar
• Greenberg A. S., Nordan R. P., McIntosh J., Calvo J. C., Scow R. O., Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3‐L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992; 52: 4113–16
   PubMed Web of Science ®Google Scholar
• Van Snick J. Interleukin‐6: an overview. Annu Rev Immunol 1990; 8: 253–78
   PubMed Web of Science ®Google Scholar
• Barzilay J. I., Abraham L., Heckbert S. R., Cushman M., Kuller L. H., Resnick H. E., et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 2384–9
   PubMed Web of Science ®Google Scholar
• Bokemark L., Wikstrand J., Attvall S., Hulthe J., Wedel H., Fagerberg B. Insulin resistance and intima‐media thickness in the carotid and femoral arteries of clinically healthy 58‐year‐old men. The Atherosclerosis and Insulin Resistance Study (AIR). J Intern Med 2001; 249: 59–67
   PubMed Web of Science ®Google Scholar
• Sjöström L. L. L., Chowdhury B., Grangård U., Lissner L., Sjöström D., . The sagittal diameter is a valid marker of the visceral adipose tissue volume. Progress in obesity research: 7, A. A. H Angel, C Bouchard, D Lau, L Leiter, R Mendelson, et al. John Libbey & Company Ltd, London 1996; 309–19
   Google Scholar
• Bokemark L., Froden A., Attvall S., Wikstrand J., Fagerberg B. The euglycemic hyperinsulinemic clamp examination: variability and reproducibility. Scand J Clin Lab Invest 2000; 60: 27–36
   PubMedGoogle Scholar
• Wendelhag I., Wiklund O., Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima‐media thickness and plaque occurrence. Arterioscler Thromb 1993; 13: 1404–11
   PubMed Web of Science ®Google Scholar
• Wendelhag I., Liang Q., Gustavsson T., Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima‐media thickness. Stroke 1997; 28: 2195–200
   PubMed Web of Science ®Google Scholar
• Schmidt C., Wendelhag I. How can the variability in ultrasound measurement of intima‐media thickness be reduced? Studies of interobserver variability in carotid and femoral arteries. Clin Physiol 1999; 19: 45–55
   PubMedGoogle Scholar
• Hulthe J., Wiklund O., Olsson G., Fagerberg B., Bokemark L., Nivall S., et al. Computerized measurement of LDL particle size in human serum. Reproducibility studies and evaluation of LDL particle size in relation to metabolic variables and the occurrence of atherosclerosis. Scand J Clin Lab Invest 1999; 59: 649–61
   PubMed Web of Science ®Google Scholar
• Wahlefeld A. W. Triglycerides: determination after enzymatic hydrolysis. Methods of enzymatic analysis, H. U Bergmeyer. Academic Press, New York 1974, 2nd English edn
   Google Scholar
• Borner K., Klose S. [Enzymatic determination of total cholesterol with the Greiner selective analyzer (GSA‐II) (author's transl)]. J Clin Chem Clin Biochem 1977; 15: 121–30
   PubMedGoogle Scholar
• Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low‐density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Grobbee D. E., Bots M. L. Carotid artery intima‐media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994; 236: 567–73
   PubMed Web of Science ®Google Scholar
• Hodis H. N., Mack W. J., LaBree L., Selzer R. H., Liu C. R., Liu C. H., et al. The role of carotid arterial intima‐media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262–9
   PubMed Web of Science ®Google Scholar
• Folsom A. R., Pankow J. S., Tracy R. P., Arnett D. K., Peacock J. M., Hong Y., et al. Association of C‐reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 112–7
   PubMedGoogle Scholar
• Sitzer M., Markus H. S., Mendall M. A., Liehr R., Knorr U., Steinmetz H. C‐reactive protein and carotid intimal medial thickness in a community population. J Cardiovasc Risk 2002; 9: 97–103
   PubMedGoogle Scholar
• van der Meer I. M., de Maat M. P., Bots M. L., Breteler M. M., Meijer J., Kiliaan A. J., et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2002; 22: 838–42
   PubMed Web of Science ®Google Scholar
• Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323–9
   PubMed Web of Science ®Google Scholar
• Fernandez‐Real J. M., Broch M., Ricart W., Casamitjana R., Gutierrez C., Vendrell J., et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998; 47: 1757–62
   PubMed Web of Science ®Google Scholar
• Hotamisligil G. S., Arner P., Atkinson R. L., Spiegelman B. M. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997; 46: 451–5
   PubMed Web of Science ®Google Scholar
• Fagerberg B., Hulthe J., Bokemark L., Wikstrand J. Low‐density lipoprotein particle size, insulin resistance, and proinsulin in a population sample of 58‐year‐old men. Metabolism 2001; 50: 120–4
   PubMed Web of Science ®Google Scholar
• Heilbronn L. K., Noakes M., Clifton P. M. Energy restriction and weight loss on very‐low‐fat diets reduce C‐reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001; 21: 968–70
   PubMed Web of Science ®Google Scholar
• Katsuki A., Sumida Y., Murashima S., Murata K., Takarada Y., Ito K., et al. Serum levels of tumor necrosis factor‐alpha are increased in obese patients with noninsulin‐dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 859–62
   PubMed Web of Science ®Google Scholar
• Vozarova B., Weyer C., Hanson K., Tataranni P. A., Bogardus C., Pratley R. E. Circulating interleukin‐6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414–7
   PubMedGoogle Scholar
• Mendall M. A., Patel P., Asante M., Ballam L., Morris J., Strachan D. P., et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78: 273–7
   PubMed Web of Science ®Google Scholar
• Straub R. H., Hense H. W., Andus T., Scholmerich J., Riegger G. A., Schunkert H. Hormone replacement therapy and interrelation between serum interleukin‐6 and body mass index in postmenopausal women: a population‐based study. J Clin Endocrinol Metab 2000; 85: 1340–4
   PubMed Web of Science ®Google Scholar